University of Massachusetts Dartmouth

Duchemin brings global MedTech leadership experience to accelerate Fotona's next phase of growth DALLAS , May 15, 2025 /PRNewswire/ -- Fotona Ⓡ, a global leader in high-performing laser systems and energy-based devices for aesthetic, dental and gynecological applications, today announces the appointment of Jeff Duchemin as Group President and CEO. Continue Reading Jeff Duchemin, CEO Fotona Duchemin brings decades of leadership experience in the global medical technology sector, having held senior roles in both U.S. and international markets. Most recently, he served in executive roles in the Interventional Surgery and Integrated Diagnostic Solutions business at Becton Dickinson along with being the former President and CEO of Harvard Biosciences. His expertise in driving revenue growth—both organically and through strategic acquisitions—will play a critical role in advancing Fotona's innovation and expanding its presence globally. Duchemin holds an M.B.A from Southern New Hampshire University and a B.S. in Accounting from the University of Massachusetts Dartmouth. "Jeff is a visionary leader with a strong track record of driving global success in the life sciences and medical device industries," said Jay Katzen, Executive Chairman, Fotona. "We are excited to have him join Fotona, which has industry leading experts and solutions, to lead Fotona through its next chapter of innovation and market leadership." "Innovation is at the heart of Fotona," said Duchemin. "I'm passionate about accelerating growth by enhancing our current solutions and introducing breakthrough technologies. Fotona has a solid foundation, exceptional talent, and world-class products. It's an honor to lead the company at such a pivotal time in its journey." Last year, Fotona proudly marked 60 years of innovation in laser technology. Throughout its history, the company has been at the forefront of industry advancements, including the groundbreaking integration of dual laser wavelengths (Er:YAG and Nd:YAG) within a single system. Most recently, Fotona launched the Dynamis® Max, its next-generation aesthetic platform offering expanded versatility, improved usability, and enhanced treatment efficiency—supporting more than 100 advanced treatment applications. For more information, visit Fotona.com. About Fotona Fotona is a world-leading medical laser company recognized for its innovative, award-winning laser systems for applications in aesthetics & dermatology, dentistry, surgery and gynecology. The company has one of the most highly educated workforces in the industry, with an exceptionally high number of PhDs specializing in laser and medical technology innovation. In addition to its direct presence in the US, China, Japan and the EU, Fotona's global distribution network spans across more than 70 countries, ensuring comprehensive support and service for Fotona laser users, including clinical training. SOURCE Fotona WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

June 22, 2021 13:00 UTC Engineering and Technology Veteran to Lead Company’s Product Vision and Support Growing Demand for Insulin Dosing Software and Inpatient Glycemic Management WALTHAM, Mass.--(BUSINESS WIRE)-- Glytec LLC, the only provider of cloud-based insulin management software across the continuum of care, today announced the appointment of Nausheen Moulana as Chief Technology Officer. In this role, Moulana will be responsible for the company’s product and technology vision, strategy and execution. A highly accomplished technologist in the healthcare, enterprise technology and scientific computing sectors, Moulana brings over 25 years of engineering and operations experience to Glytec. She possesses a deep understanding of developing complex software products and driving process improvement to maximize customer value. Moulana comes to Glytec from Kyruus, the leader in provider search and scheduling solutions for health systems, where she served as Vice President of Engineering & Operations and led multiple teams tasked with delivering multi-channel patient access solutions. She also previously held leadership positions at Attivio (since acquired by ServiceNow) and MathWorks. “Thousands of hospitals across the country still rely on dated paper protocols to titrate insulin and manage inpatient blood glucose levels. The opportunity for advanced software to simplify these processes and improve patient safety and care is massive,” said Moulana. “I’m honored to join the growing team at Glytec to address this challenge and further revolutionize the way providers care for patients that require insulin in the hospital setting.” In April 2021, Glytec closed a $21 million funding round to put significant resources behind accelerating research and product development and scaling into hospitals across the United States. In her new role, Moulana will lead the teams responsible for creating the innovations that continue to strengthen Glytec’s position as the industry leader in insulin management and patient safety. The Product Development teams will focus on enhancements in provider workflows, EHR integrations, mobile apps at scale and support for other diabetes technology across the continuum of care. “This has been a record year for Glytec and adding a proven technology leader like Nausheen to the Executive team only builds upon that momentum,” said Ed Furlong, President and Chief Executive Officer, Glytec. “The past year has illuminated the importance of properly managing glycemic issues, especially in the hospital setting. Nausheen will help us meet the growing demand for eGlycemic Management System, enabling Glytec to remain the industry leader for inpatient glycemic management.” Moulana holds a Master of Science in Electrical Engineering from the University of Massachusetts Dartmouth and a Master of Business Administration from Babson College. Known for her mentorship approach to leadership and advocacy for diversity, equity and inclusion, Moulana is also a startup advisor, speaker and host for several technical and talent events. To learn more about Glytec, visit: . About Glytec Glytec is the insulin management software company for healthcare providers focused on improving the quality and cost of care. Its FDA-cleared titration software and proprietary algorithms power the only solution capable of delivering personalized diabetes treatment recommendations across the continuum of care, from hospital to home. With ongoing support from its team of doctors, nurses and technologists headquartered outside of Boston, Glytec improves outcomes and controls costs for the large population of patients requiring insulin treatment – including those with and without a diagnosis of diabetes. For more information, follow Glytec on Twitter (@Glytec) and LinkedIn, or visit . MAR-0000344 Rev. 1.0